Get the Stockscreener App
6.30
0.96%
0.06
After Hours:
6.30
Quantum Biopharma Ltd stock is traded at $6.30, with a volume of 27,129.
It is up +0.96% in the last 24 hours and down -12.26% over the past month.
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.
See More
Previous Close:
$6.24
Open:
$6.18
24h Volume:
27,129
Relative Volume:
0.01
Market Cap:
$15.45M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-5.83%
1M Performance:
-12.26%
6M Performance:
+9.57%
1Y Performance:
+0.00%
1-Day Range:
$6.0657
$6.43
1-Week Range:
$5.9354
$7.33
52-Week Range:
$2.70
$18.00
Quantum Biopharma Ltd Stock (QNTM) Company Profile
Compare QNTM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNTM
Quantum Biopharma Ltd
|
6.30 | 15.45M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
148.67 | 67.28B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.22 | 45.62B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.71 | 45.01B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.65 | 15.60B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
284.73 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Quantum Biopharma Ltd Stock (QNTM) Latest News
Quantum BioPharma Corporate Update - Newsfile
West Fraser Timber Ltd Stock Analysis: Q1 2025 Earnings and Future Outlook - The Globe and Mail
Meta Platforms (META) Can Withstand an Advertising Slowdown, Says Citigroup - The Globe and Mail
Allied Announces April 2025 Distribution - The Globe and Mail
Abbott Laboratories (ABT) Q1 Earnings: What To Expect - The Globe and Mail
Quantum Biopharma Wins Reconsideration Motion by Dr. Raza Bokhar - GuruFocus
Quantum BioPharma (QNTM) Prevails in Legal Dispute with Former C - GuruFocus
Market Analysis: April 14th, 2025 - The Globe and Mail
Quantum BioPharma wins legal battle against former CEO By Investing.com - Investing.com Canada
3 Hot New IPOs Defying the 2025 Market Slump - The Globe and Mail
Canadian Insurance Market Remains Strong Amidst Market Volatility: Aon Report - The Globe and Mail
Quantum BioPharma Secures Legal Victory with $180,000 Award - TipRanks
Quantum BioPharma wins legal battle against former CEO - Investing.com
Quantum Biopharma Wins Reconsideration Motion by Dr. Raza Bokhari at the Court of Appeal for Ontario - GlobeNewswire
Latest: Court Upholds $2.8M Award in Quantum BioPharma's Favor Against Former CEO - Stock Titan
2 AI Stocks That Could Help Set You Up for Life - The Globe and Mail
3 ETFs to Save Your Portfolio Right Now - The Globe and Mail
Are These 3 Retail Stocks Oversold or Really in Trouble? - The Globe and Mail
BMO Announces Election of Board of Directors - The Globe and Mail
Stocks in play: Bonterra Energy Corp - The Globe and Mail
Time to Load Up on the New Look of SCHD - The Globe and Mail
1 Undervalued Growth Stock You Can Buy During the Stock Market Drop of 2025 - The Globe and Mail
3 Reasons to Avoid SWIM and 1 Stock to Buy Instead - The Globe and Mail
Quantum BioPharma Licensee Celly Nutrition Announces Landmark Pa - GuruFocus
Quantum BioPharma’s licensee expands retail reach with AATAC deal By Investing.com - Investing.com South Africa
Quantum BioPharma Licensee Celly Nutrition Partners With Asian American Trade Associations Council - marketscreener.com
Quantum BioPharma's licensee expands retail reach with AATAC deal By Investing.com - Investing.com India
Quantum BioPharma's licensee expands retail reach with AATAC deal - Investing.com
Quantum BioPharma Licensee Celly Nutrition Announces Landmark Partnership with the Asian American Trade Associations Council (AATAC) to Expand Retail Availability of its Alcohol Detox Beverage unbuzzd™ - GlobeNewswire
Quantum's Alcohol Detox Drink Lands Massive Deal: Coming to 80,000+ US Stores - Stock Titan
Altair Wins 2025 Google Cloud Business Applications Partner of the Year Award for Manufacturing - The Globe and Mail
Press Release Distribution & PR Platform - ACCESS Newswire
Taiwan Semi Stock’s (TSM) Selloff Is ‘Overdone,’ Says BofA - The Globe and Mail
Micro Cap AI Distributor Defies Market Weakness with Record Revenue and Rising Margins - The Globe and Mail
Levi's (LEVI) Reports Q1: Everything You Need To Know Ahead Of Earnings - The Globe and Mail
Lancaster Colony Stock (LANC) Defies Down Market on Record-Breaking Sales Performance - The Globe and Mail
Gentex Schedules First Quarter 2025 Earnings Release Date and Conference Call - The Globe and Mail
Quantum BioPharma’s ‘unbuzzd’ Launches in Puerto Rico - TipRanks
Quantum BioPharma Licensee Celly Nutrition Launches unbuzzd in Puerto Rico - The Manila Times
Quantum BioPharma Licensee Celly Nutrition Launches Unbuzzd In Puerto Rico - Barchart.com
Auto Tariffs Upending Global Trade: These Stocks Can Win No Matter What Happens Next - The Globe and Mail
Quantum BioPharma stock soars on clinical trial success By Investing.com - Investing.com Nigeria
Quantum Biopharma to Jointly Study Demyelination Imaging Technique With Massachusetts Hospital - MarketScreener
Quantum BioPharma in Joint Clinical Study With Massachusetts Hospital to Assess PET Imaging - marketscreener.com
Quantum BioPharma Announces Joint Clinical Study With Massachusetts General Hospital Scientists to Validate a Novel Positron Emission Tomography (PET) Imaging Technique to Monitor Demyelination In Multiple Sclerosis - The Manila Times
Game-Changing MS Detection: Quantum's New PET Technology Could Outperform Traditional MRI - Stock Titan
Quantum BioPharma completes $5 million funding round By Investing.com - Investing.com Canada
Quantum BioPharma completes $5 million funding round - Investing.com
Quantum BioPharma Secures Final Tranche of $5 Million Financing - TipRanks
Quantum Biopharma Announces Closing of Final $2.42 Million - GlobeNewswire
Quantum BioPharma Closes $5M Deal While Unveiling Revolutionary Emergency Alcohol Treatment - Stock Titan
Quantum Biopharma Ltd Stock (QNTM) Financials Data
There is no financial data for Quantum Biopharma Ltd (QNTM). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.74%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):